Viridian Therapeutics, Inc.\DE

For the period ended Sep 30, 2026. Filed Nov 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 4, 2026

VRDN$30.86+2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share data)

Convertible Preferred Stock · Common Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders’Equity
Series A · Series B
Shares · Amount · Shares · Amount · Shares · Amount
Balance as of December 31, 2025	134,864		$61,188			79,620		$70,868			101,826,500			$1,018		$1,927,104		$447		$(1,338,458)		$722,167
Issuance of common stock upon exercises of stock options	—		—			—		—			424,648			5		6,352		—		—		6,357
Issuance of common stock upon vesting of restricted stock units	—	—			—		—			206,946		2			(2)		—		—		—
Share-based compensation expense	—		—			—		—			—			—		13,390		—		—		13,390
Unrealized loss on available-for-sale securities	—		—			—		—			—			—		—		(1,008)		—		(1,008)
Change in cumulative translation adjustment	—	—			—		—			—		—			—		3		—		3
Net loss	—		—			—		—			—			—		—		—		(104,901)		(104,901)
Balance as of March 31, 2026	134,864		$61,188			79,620		$70,868			102,458,094			$1,025		$1,946,844		$(558)		$(1,443,359)		$636,008
Issuance of common stock upon conversion of convertible preferred stock	(1,673)		(756)			(31,157)		(33,276)			2,188,771			22		34,010		—		—		—
Issuance of common stock in an underwritten offering, net of issuance costs of $8,778	—		—			—		—			8,455,883			85		134,887		—		—		134,972
Issuance of common stock upon exercises of stock options	—		—			—		—			41,646			—		577		—		—		577
Issuance of common stock under employee stock purchase plan	—	—		—		—	92,842		—		1,270		—		—	1,270
Issuance of common stock upon vesting of restricted stock units	—		—			—		—			982			—		—		—		—		—
Share-based compensation expense	—		—			—		—			—			—		16,984		—		—		16,984
Unrealized loss on available-for-sale securities	—		—			—		—			—			—		—		(598)		—		(598)
Change in cumulative translation adjustment	—		—			—		—			—			—		—		3		—		3
Net loss	—		—			—		—			—			—		—		—		(127,119)		(127,119)
Balance as of June 30, 2026	133,191		$60,432			48,463		$37,592			113,238,218			$1,132		$2,134,572		$(1,153)		$(1,570,478)		$662,097
Issuance of common stock upon exercises of stock options	—	—			—		—			260,004		3			3,623		—		—		3,626
Issuance of common stock upon vesting of restricted stock units	—	—			—		—			27,000		—			—		—		—		—
Share-based compensation expense	—	—			—		—			—		—			17,232		—		—		17,232
Unrealized loss on available-for-sale securities	—	—			—		—			—		—			—		(1,020)		—		(1,020)
Change in cumulative translation adjustment	—		—			—		—			—			—		—		(28)		—		(28)
Net loss	—	—			—		—			—		—			—		—		(101,209)		(101,209)
Balance as of September 30, 2026	133,191		$60,432			48,463		$37,592			113,525,222			$1,135		$2,155,427		$(2,201)		$(1,671,687)		$580,698

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except share data)

Convertible Preferred Stock · Common Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders’Equity
Series A · Series B
Shares · Amount · Shares · Amount · Shares · Amount
Balance as of December 31, 2024	134,864	$61,188	145,160		$127,697		80,994,046	$810		$1,477,811		$(10)		$(995,857)		$671,639
Issuance of common stock in at-the-market offerings, net of issuance costs of $149	—	—	—		—		245,388		3		4,792		—		—		4,795
Issuance of common stock upon exercises of warrants	—	—	—		—		115,146		1		1,617		—		—		1,618
Issuance of common stock upon exercises of stock options	—	—	—		—		185,426		2		2,295		—		—		2,297
Issuance of common stock under employee stock purchase plan	—	—	—		—		41,106		—		561		—		—		561
Issuance of common stock upon vesting of restricted stock units	—	—	—		—		8,315		—		—		—		—		—
Share-based compensation expense	—	—	—		—		—		—		10,220		—		—		10,220
Unrealized gain on available-for-sale securities	—	—	—		—		—		—		—		255		—		255
Net loss	—	—	—		—		—		—		—		—		(86,912)		(86,912)
Balance as of March 31, 2025	134,864	$61,188	145,160		$127,697		81,589,427		$816		$1,497,296		$245		$(1,082,769)		$604,473
Issuance of common stock upon exercises of stock options	—	—	—		—		61,527		1		762		—		—		763
Issuance of common stock upon vesting of restricted stock units	—	—	—		—		232		—		—		—		—		—
Share-based compensation expense	—	—	—		—		—		—		10,844		—		—		10,844
Unrealized loss on available-for-sale securities	—	—	—		—		—		—		—		(176)		—		(176)
Net loss	—	—	—		—		—		—		—		—		(100,735)		(100,735)
Balance as of June 30, 2025	134,864	$61,188	145,160		$127,697		81,651,186		$817		$1,508,902		$69		$(1,183,504)		$515,169
Issuance of common stock, March2025 ATM, net of issuance costs of $209	—	—	—		—		500,000		5		9,746		—		—		9,751
Issuance of common stock upon exercises of stock options	—	—	—		—		34,522		—		547		—		—		547
Issuance of common stock under employee stock purchase plan				43,450		—		558		—		—		558
Share-based compensation expense	—	—	—		—		—		—		11,250		—		—		11,250
Unrealized gain on available-for-sale securities	—	—	—		—		—		—		—		294		—		294
Net loss	—	—	—		—		—		—		—		—		(34,599)		(34,599)
Balance as of September 30, 2025	134,864	$61,188	145,160		$127,697		82,229,158		$822		$1,531,003		$363		$(1,218,103)		$502,970

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.